• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上皮性卵巢癌:初次手术与术后化疗之间的时间间隔有预后意义吗?

Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?

作者信息

Larsen Erling, Blaakaer Jan

机构信息

Department of Gynecology and Obstetrics, Aarhus University Hospital, Denmark.

出版信息

Acta Obstet Gynecol Scand. 2009;88(4):373-7. doi: 10.1080/00016340902814559.

DOI:10.1080/00016340902814559
PMID:19253061
Abstract

Worldwide, much effort is used every day to perform optimal surgery in the treatment of epithelial ovarian cancer. Treatment of ovarian cancer is a combination of surgery with optimal debulking followed by chemotherapy. However, the optimal timing of postoperative chemotherapy for ovarian cancer remains poorly defined. The literature is made up of seven studies performed in different ways and which have included varying prognostic factors. The general supposition is that the time interval (TI) does not have a prognostic influence but experimental studies have shown that it does affect the prognosis of the cancer. This commentary focuses on the importance of the TI between surgery and postoperative chemotherapy in this horrible disease.

摘要

在全球范围内,每天都投入大量精力为上皮性卵巢癌患者实施最佳手术治疗。卵巢癌的治疗是手术与最佳肿瘤细胞减灭术相结合,随后进行化疗。然而,卵巢癌术后化疗的最佳时机仍不明确。相关文献由七项采用不同方法开展的研究组成,这些研究纳入了各不相同的预后因素。一般的推测是时间间隔(TI)没有预后影响,但实验研究表明它确实会影响癌症的预后。本述评聚焦于在这种可怕疾病中手术与术后化疗之间时间间隔的重要性。

相似文献

1
Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?上皮性卵巢癌:初次手术与术后化疗之间的时间间隔有预后意义吗?
Acta Obstet Gynecol Scand. 2009;88(4):373-7. doi: 10.1080/00016340902814559.
2
[Time interval between ovarian cancer surgery and chemotherapy--secondary publication?].
Ugeskr Laeger. 2009 Nov 2;171(45):3265-8.
3
The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.新辅助化疗后卵巢癌的最佳肿瘤细胞减灭术:基于一线手术治疗期间间隔观察的建议。
Jpn J Clin Oncol. 2010 Jan;40(1):36-41. doi: 10.1093/jjco/hyp127. Epub 2009 Oct 10.
4
Surgical management of epithelial ovarian cancer: a review of the literature.上皮性卵巢癌的外科治疗:文献综述
Minerva Ginecol. 2004 Dec;56(6):547-56.
5
Advances in treatment of epithelial ovarian cancer.上皮性卵巢癌的治疗进展
Nagoya J Med Sci. 2006 Jan;68(1-2):19-26.
6
Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.新辅助化疗联合延迟初次手术减瘤治疗的晚期上皮性卵巢癌患者术后并发症的预后意义
Ann Surg Oncol. 2006 Dec;13(12):1711-6. doi: 10.1245/s10434-006-9125-6. Epub 2006 Sep 29.
7
Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
Zhonghua Yi Xue Za Zhi (Taipei). 2000 Mar;63(3):220-5.
8
Retrospective study of the prognostic factors of remission induction for single-agent chemotherapy with cisplatin in advanced epithelial ovarian cancer.
Oncol Rep. 2000 Mar-Apr;7(2):311-3.
9
Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.新辅助化疗能否提高晚期卵巢癌的最佳肿瘤细胞减灭率?21项研究的荟萃分析
Ann Surg Oncol. 2009 Aug;16(8):2315-20. doi: 10.1245/s10434-009-0558-6. Epub 2009 Jun 11.
10
Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.晚期上皮性卵巢癌患者化疗前后游离血浆DNA的定量分析。
Diagn Mol Pathol. 2008 Mar;17(1):34-8. doi: 10.1097/PDM.0b013e3181359e1f.

引用本文的文献

1
The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study.初次细胞减灭性手术与肠切除术后至辅助化疗开始时间间隔对晚期卵巢癌患者生存的影响:一项多中心队列研究。
J Gynecol Oncol. 2022 Nov;33(6):e76. doi: 10.3802/jgo.2022.33.e76. Epub 2022 Aug 4.
2
Survival and prognostic factors in women treated for epithelial ovarian cancer in western region of Saudi Arabia.在沙特阿拉伯西部地区接受上皮性卵巢癌治疗的女性的生存和预后因素。
Saudi Med J. 2022 Feb;43(2):146-155. doi: 10.15537/smj.2022.43.2.20210626.
3
A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin.
新辅助化疗后间隔细胞减灭术的小鼠模型表明围手术期顺铂疗效受损。
J Ovarian Res. 2021 Nov 16;14(1):157. doi: 10.1186/s13048-021-00895-w.
4
Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.与韩国和中国台湾两所大型学术机构的低级别浆液性卵巢癌预后相关的临床因素。
Sci Rep. 2020 Nov 17;10(1):20012. doi: 10.1038/s41598-020-77075-1.
5
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.二次细胞减灭术后至辅助化疗的间隔时间与复发性卵巢癌患者的生存无关。
J Ovarian Res. 2019 Dec 31;13(1):1. doi: 10.1186/s13048-019-0602-5.
6
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.辅助治疗开始时间与早期卵巢癌患者生存率的关联——NRG肿瘤学/妇科肿瘤学组试验分析
Gynecol Oncol. 2016 Dec;143(3):490-495. doi: 10.1016/j.ygyno.2016.09.015. Epub 2016 Oct 19.
7
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.初步研究:肝癌缺失基因1和磷酸化粘着斑激酶Y397在晚期上皮性卵巢癌中的表达变化及其预后价值
Int J Mol Sci. 2011;12(12):8489-501. doi: 10.3390/ijms12128489. Epub 2011 Nov 29.